Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD07 in advanced Claudin18.2 positive solid tumors
NCT05284968Phase 1Unknown
- Sponsor
- Peking University
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label trial of RD07 cell injection in gastric cancer (GC), gastroesophageal junction adenocarcinoma, pancreatic cancer (PC) and 1 more, sponsored by Peking University. Primary endpoint: Dose-limiting toxicity and maximum tolerated dose at 3 years. Status: unknown.
02
Drugs
RD07 cell injection
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomapancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT05284968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284968.